Results 91 to 100 of about 471 (127)
Kalaivani Ramakrishnan +4 more
openaire +1 more source
New Antibiotics for Treating Infections Caused by Multidrug-Resistant Bacteria. [PDF]
Machado E, Sousa JC.
europepmc +1 more source
How I manage patients with New Delhi metallo-beta-lactamase and OXA-48-producing Enterobacterales infections: a practical approach. [PDF]
Tiseo G, Galfo V, Falcone M.
europepmc +1 more source
Emergence and characterization of new OXA-181 variants in France: OXA-1181, OXA-1201, OXA-1205, OXA-1207, and OXA-1226. [PDF]
Bientz L +5 more
europepmc +1 more source
In Vitro efficacy of Cefepime/Enmetazobactam against AmpC ßlactamase-producing Enterobacterales
Marlat, Clément +6 more
openaire +1 more source
Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. [PDF]
Cefepime-enmetazobactam is a novel β-lactam–β-lactamase inhibitor combination with broad-spectrum antimicrobial activity against a range of multidrug-resistant Enterobacteriaceae . This agent is being developed for a range of serious hospital infections.
William Hope, Jesús Reiné, Elena Mitsi
exaly +5 more sources
Cefepime/enmetazobactam is a novel β-lactam/β-lactamase inhibitor (BL-BLI) combination with broad Gram-positive and -negative activity. Cefepime is relatively resistant to hydrolysis by AmpC, and enmetazobactam inhibits all Ambler Class A extended spectrum β-lactamases (ESBLs). Hence, the combination is resistant to hydrolysis by many ESBLs.
William Hope +2 more
exaly +4 more sources

